How Valeda Works
Valeda uses light-emitting diodes (LEDs) to stimulate cellular function, leading to improved energy production within the mitochondria.
Valeda delivers wavelengths of 590, 660, and 850 nm. In the scientific literature, these wavelengths address independent cellular mechanisms that are important in age-related macular degeneration (AMD).
Both the 660 and 850 nm wavelengths were chosen based on their known interaction with cellular photoacceptors in cytochrome c oxidase (CCO). The 660 and 850 nm wavelengths promote electron transfer and oxygen binding, respectively, in CCO leading to restoration of mitochondria function and increases in metabolic activity (i.e., energy production), and inhibition in inflammatory events and cell death.
The 590 nm naturally inhibits expression of vascular endothelial growth factor (VEGF), a signaling protein that stimulates the formation of blood vessels that contributes to the development of the wet-form of AMD. It also increases the signaling protein, nitric oxide which reduces oxidative stress-mediated injury in the cell and increases local O2 delivery.
- Wavelength 8502
Drives electron transfer (CUA) stimulates metababolic activity (ATP) and inhibits inflammation and cell death
- Wavelength 6602
Promotes O2 binding (CUB), stimulates metababolic activity (ATP) and inhibits inflammation and cell death
- Wavelength 6603, 4
inhibits VEGF expression and promotes nitric oxide generation
Valeda In Clinical Practice
Valeda is a medical device designed for ease of use in the clinician’s office
Valeda is the first and only PBM device designed specifically for ophthalmic applications.
Treatments are delivered in a series of 9 sessions per eye over a three-week period. Each treatment session lasts less than 5 minutes per eye.
Valeda is the only PBM device to be granted CE Mark Certification for medical claims associated with the treatment of ocular diseases and disorders including dry age-related macular degeneration.
Indications for Use: The indicated use is for treatment of ocular damage and disease using photobiomodulation, including inhibition of inflammatory mediators, edema or drusen deposition, improvement of wound healing following ocular trauma or surgery, and increase in visual acuity and contrast sensitivity in patients with degenerative diseases such as dry age-related macular degeneration.